drugset / Trial / NCT07540442
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Timeline
- Start
- 2026-04-17
- Primary completion
- 2027-01-05
- Completion
- 2027-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COMEKIBART | Monoclonal antibody | — | Subcutaneous |